SCM
GPCR icon

Soleus Capital Management’s Structure Therapeutics GPCR Stock Holding History

Soleus Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74M Buy
107,000
+27,000
+34% +$1.19M 0.2% 73
2026
Q1 		$3.86M Sell
80,000
-10,000
-11% -$684K 0.16% 70
2025
Q4 		$6.26M Buy
+90,000
New +$3.67M 0.23% 63

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Soleus Capital Management's GPCR Position: Q2 2026 in Review

Soleus Capital Management increased its Structure Therapeutics (GPCR) stake by 34% in Q2 2026, buying an estimated $1.19M and bringing the position to 107,000 shares worth $5.74M. The position accounts for 0.2% of the portfolio, ranked #73.

Soleus Capital Management first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.26M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Soleus Capital Management held 107,000 shares of Structure Therapeutics worth $5.74M as of Q2 2026.
  • Soleus Capital Management bought 27,000 Structure Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Structure Therapeutics made up 0.2% of Soleus Capital Management's portfolio in Q2 2026, its #73 holding.
  • Soleus Capital Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Soleus Capital Management's Structure Therapeutics position peaked at $6.26M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.